Literature DB >> 20550594

Methodologic evaluation of adaptive conjoint analysis to assess patient preferences: an application in oncology.

Arwen H Pieterse1, Anne M Stiggelbout, Corrie A M Marijnen.   

Abstract

BACKGROUND: Adaptive conjoint analysis (ACA) is an individually tailored preferences elicitation technique that mimics actual decision-making processes by asking participants to make trade-offs between the various dimensions that underlie decision problems. ACA is increasingly applied in patient preferences assessments but formal evaluation of its validity and reliability is lacking.
OBJECTIVE: To investigate ACA's validity and reliability in elicitation of treatment outcome preferences.
METHODS: Sixty-eight disease-free rectal cancer patients, treated with surgery with or without preoperative radiotherapy were asked to complete exercises to assess their preferences for radiotherapy [using the treatment trade-off method (TTM)] and for key outcomes associated with radiotherapy (using ACA). We assessed (i) rank ordering of ACA-derived outcome-probability utilities, (ii) compensatory decision making, (iii) ACA test-retest reliability, and (iv) concordance of ACA- and TTM-based preferences.
RESULTS: All participants completed the TTM and 66 completed the ACA questionnaire, in 15 min on average. Outcome utilities were rank ordered in agreement with probabilities from best to worst in most participants, except for sexual dysfunction. Most participants were willing to trade survival and their most important outcome. Mean importance ratings were similar at retest. ACA- and TTM-based preferences differed. TTM-based preferences were related to past treatment, ACA-based preferences were not.
CONCLUSIONS: ACA assesses group-level preferences reliably over time and captures individual preferences independently from treatment experience in treated cancer patients. ACA seems a valid treatment outcome preference elicitation method in a context in which trade-offs between cure and quality of life need to be considered.
© 2010 The Authors. Health Expectations © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20550594      PMCID: PMC5060551          DOI: 10.1111/j.1369-7625.2010.00595.x

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  40 in total

1.  The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life.

Authors:  M A Sprangers; A te Velde; N K Aaronson
Journal:  Eur J Cancer       Date:  1999-02       Impact factor: 9.162

2.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

Review 3.  Doing the right thing: systems support for decision quality in cancer care.

Authors:  Karen Sepucha; Elissa Ozanne; Albert G Mulley
Journal:  Ann Behav Med       Date:  2006-12

4.  Surveillance versus adjuvant chemotherapy in stage I non-seminomatous testicular cancer: a decision analysis.

Authors:  A M Stiggelbout; G M Kiebert; J C de Haes; H J Keizer; G Stoter; R de Wit; J B Vermorken; J W Leer; J Kievit
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

5.  The effect of search procedures on utility elicitations.

Authors:  L A Lenert; D J Cher; M K Goldstein; M R Bergen; A Garber
Journal:  Med Decis Making       Date:  1998 Jan-Mar       Impact factor: 2.583

6.  Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial.

Authors:  Corrie A M Marijnen; Cornelis J H van de Velde; Hein Putter; Mandy van den Brink; Cornelis P Maas; Hendrik Martijn; Harm J Rutten; Theo Wiggers; Elma Klein Kranenbarg; Jan-Willem H Leer; Anne M Stiggelbout
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

7.  Patient preferences and clinical guidelines.

Authors:  M A Hlatky
Journal:  JAMA       Date:  1995-04-19       Impact factor: 56.272

8.  Trading treatment toxicity for survival in locally advanced non-small cell lung cancer.

Authors:  M D Brundage; J R Davidson; W J Mackillop
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

9.  Patient preferences for acute pain treatment.

Authors:  T J Gan; D A Lubarsky; E M Flood; T Thanh; J Mauskopf; T Mayne; C Chen
Journal:  Br J Anaesth       Date:  2004-03-05       Impact factor: 9.166

10.  Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?

Authors:  S J Jansen; J Kievit; M A Nooij; J C de Haes; I M Overpelt; H van Slooten; E Maartense; A M Stiggelbout
Journal:  Br J Cancer       Date:  2001-06-15       Impact factor: 7.640

View more
  4 in total

1.  Use of Conjoint Analysis to Determine Patient Preferences for Surgical Treatment of Urethral Stricture Disease.

Authors:  Leslie Wilson; Tracy Kuo Lin; Lindsay A Hampson; Anna Oh; Jie Ting; Thomas Gaither; Isabel Allen; Benjamin N Breyer
Journal:  J Particip Med       Date:  2017-01-14

Review 2.  Discrete choice experiments in health economics: a review of the literature.

Authors:  Michael D Clark; Domino Determann; Stavros Petrou; Domenico Moro; Esther W de Bekker-Grob
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

Review 3.  Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?

Authors:  Bengt Glimelius
Journal:  Front Oncol       Date:  2014-04-07       Impact factor: 6.244

Review 4.  Empowering patients in decision-making in radiation oncology - can we do better?

Authors:  Michelle Leech; Matthew S Katz; Joanna Kazmierska; Julie McCrossin; Sandra Turner
Journal:  Mol Oncol       Date:  2020-04-13       Impact factor: 6.603

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.